Efter aflæggelse af Q1 regnskabet afholdt Genmabs ledelse med analytikerne deres investorpræsentation, som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Genmab indleder præsentationen sådan:
Strategic Partnerships, Collaborations and Licensing Agreements
As part of the Genmab First Quarter End Results presentation, we will discuss several products developed in collaboration with strategic partners or that are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships.
• Partners for Genmab owned products ≥50%:
• Seagen Inc.: tisotumab vedotin
• AbbVie Inc.: epcoritamab, DuoHexaBody-CD37 (GEN3009), DuoBody-CD3x5T4
(GEN1044)
• BioNTech SE: DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042)
• Janssen Biotech, Inc.: HexaBody-CD38 (GEN3014)
• Companies developing products created by Genmab or that incorporate Genmab’s innovation:
• Janssen Biotech, Inc.: daratumumab, amivantamab
• Novartis: ofatumumab
• Horizon Therapeutics: teprotumumab
